These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19664812)

  • 1. Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer.
    Zivanovic O; Sima CS; Iasonos A; Bell-McGuinn KM; Sabbatini PJ; Leitao MM; Levine DA; Gardner GJ; Barakat RR; Chi DS
    Gynecol Oncol; 2009 Nov; 115(2):209-14. PubMed ID: 19664812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum.
    Zivanovic O; Sima CS; Iasonos A; Hoskins WJ; Pingle PR; Leitao MM; Sonoda Y; Abu-Rustum NR; Barakat RR; Chi DS
    Gynecol Oncol; 2010 Mar; 116(3):351-7. PubMed ID: 20022092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy.
    Rodriguez N; Rauh-Hain JA; Shoni M; Berkowitz RS; Muto MG; Feltmate C; Schorge JO; Del Carmen MG; Matulonis UA; Horowitz NS
    Gynecol Oncol; 2012 May; 125(2):362-6. PubMed ID: 22333992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.
    Rocconi RP; Matthews KS; Kemper MK; Hoskins KE; Huh WK; Straughn JM
    Gynecol Oncol; 2009 Aug; 114(2):242-5. PubMed ID: 19447480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction?
    Perri T; Ben-Baruch G; Kalfon S; Beiner ME; Helpman L; Hogen LB; Shapira-Frommer R; Korach J
    Gynecol Oncol; 2013 Oct; 131(1):27-31. PubMed ID: 23880152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172.
    Krivak TC; Tian C; Rose GS; Armstrong DK; Maxwell GL
    Gynecol Oncol; 2009 Oct; 115(1):81-85. PubMed ID: 19596139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of various kinetic parameters of CA-125 in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy.
    Lee YJ; Lee IH; Kim YJ; Chung YS; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
    PLoS One; 2018; 13(9):e0203366. PubMed ID: 30188915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature.
    Loizzi V; Leone L; Camporeale A; Resta L; Selvaggi L; Cicinelli E; Cormio G
    Oncology; 2016; 91(4):211-216. PubMed ID: 27487241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
    Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.
    Zwakman N; van de Laar R; Van Gorp T; Zusterzeel PL; Snijders MP; Ferreira I; Massuger LF; Kruitwagen RF
    J Gynecol Oncol; 2017 Jan; 28(1):e7. PubMed ID: 27670261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer.
    Isonishi S; Niimi S; Sasaki H; Ochiai K; Yasuda M; Tanaka T
    Gynecol Oncol; 2004 Jun; 93(3):647-52. PubMed ID: 15196859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy.
    Eisenhauer EL; Tew WP; Levine DA; Lichtman SM; Brown CL; Aghajanian C; Huh J; Barakat RR; Chi DS
    Gynecol Oncol; 2007 Aug; 106(2):381-7. PubMed ID: 17509673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer--a study by the OVCAD consortium.
    Melmer A; Fineder L; Lamina C; Kollerits B; Dieplinger B; Braicu I; Sehouli J; Cadron I; Vergote I; Mahner S; Zeimet AG; Castillo-Tong DC; Ebenbichler CF; Zeillinger R; Dieplinger H
    Gynecol Oncol; 2013 Jan; 128(1):38-43. PubMed ID: 23063758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
    Kang WD; Choi HS; Kim SM
    Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
    Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Aghajanian C; Barakat RR; Chi DS
    Gynecol Oncol; 2008 Feb; 108(2):276-81. PubMed ID: 18063020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of serum CA(125) detection for predicting recurrence and prognosis in ovarian epithelial cancer].
    Wang XY; Ye J; Feng SW; Lü WG; Wan XY; Xie X
    Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):813-6. PubMed ID: 21211277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
    Zhang J; Liu N; Zhang A; Bao X
    J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer.
    Prat A; Parera M; Peralta S; Perez-Benavente MA; Garcia A; Gil-Moreno A; Martinez-Palones JM; Roxana I; Baselga J; Del Campo JM
    Ann Oncol; 2008 Feb; 19(2):327-31. PubMed ID: 18065408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.